Background:
hepatic impairment, cirrhosis
HEPATIC IMPAIRMENT, CIRRHOSIS, PORTAL HYPERTENSION, COMPLICATION
Portal hypertension is a severe complication of cirrhosis. This Phase Ib study (NCT03842761) assessed the safety, tolerability, and pharmacokinetics of soluble guanylyl cyclase activator BI 685509 in patients with mild or moderate hepatic impairment (Child–Pugh [CP] A or B cirrhosis) and healthy volunteers (HVs).